Side Effects of empagliflozin: A Synthesis of Findings from 20 Studies

  1. Home
  2. Side Effects of empagliflozin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of empagliflozin: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of empagliflozin: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Empagliflozin is a new drug used to treat type 2 diabetes. Empagliflozin works by blocking the reabsorption of glucose in the kidneys, which increases the amount of glucose excreted in the urine and lowers blood sugar levels. 1 It is also hoped to have a preventative effect on heart disease and kidney disease. 14

Empagliflozin is widely used as a diabetes medication, but some side effects have been reported. 1 Side effects of empagliflozin include urinary tract infections, hypoglycemia, dehydration, and ketoacidosis. 9

Empagliflozin is a new drug, and its side effects have not been fully elucidated. 1 It is important to understand the risks and benefits of empagliflozin before using it. 13

Reasons for Side Effects

Empagliflozin works by blocking the reabsorption of glucose in the kidneys, which increases the amount of glucose excreted in the urine and lowers blood sugar levels. 1 However, this effect can also increase the amount of water excreted in the urine, which can lead to dehydration. 9 Empagliflozin also has the effect of suppressing insulin secretion, which can lead to hypoglycemia. 9

Common Side Effects

Urinary Tract Infections

Empagliflozin increases the amount of glucose excreted in the urine, which can increase the risk of urinary tract infections. 1

Hypoglycemia

Empagliflozin also has the effect of suppressing insulin secretion, which can lead to hypoglycemia. 9

Dehydration

Empagliflozin can increase the amount of water excreted in the urine, which can lead to dehydration. 9

Ketoacidosis

Empagliflozin also has the effect of suppressing insulin secretion, which can lead to ketoacidosis. 9

Acute Pancreatitis

Empagliflozin may cause acute pancreatitis. 1

Heart Failure

Empagliflozin may worsen heart failure. 7

Kidney Disease

Empagliflozin may worsen kidney disease. 7

Side Effect Management

Urinary Tract Infections

If you experience symptoms of a urinary tract infection, see your doctor.

Hypoglycemia

If you experience symptoms of hypoglycemia, quickly consume glucose.

Dehydration

It is important to drink plenty of fluids to prevent dehydration.

Ketoacidosis

If you experience symptoms of ketoacidosis, see your doctor immediately.

Comparison Between Studies

Commonalities in Research

Multiple studies have shown that empagliflozin is effective in treating type 2 diabetes. However, it is also clear that empagliflozin can cause some side effects. It is important to understand the risks and benefits of empagliflozin before using it.

Differences in Research

Multiple studies have shown that the frequency and severity of empagliflozin side effects vary. This may be due to a variety of factors, such as the age, sex, severity of diabetes, and other medications used by the research participants. Further research is needed on the side effects of empagliflozin.

Considerations for Applying Research to Real Life

Empagliflozin is an effective medication for treating type 2 diabetes, but it can cause some side effects. 1 It is important to understand the risks and benefits of empagliflozin before using it. 13 In particular, elderly patients and those with underlying conditions such as kidney disease may be at increased risk of side effects. 9 When using empagliflozin, you should see your doctor regularly and carefully monitor for any side effects.

Current Research Limitations

Empagliflozin is a new drug, and its side effects have not been fully elucidated. Further research is needed on the side effects of empagliflozin.

Future Research Directions

Research is needed to evaluate the long-term safety and effectiveness of empagliflozin. 19 Research is also needed to reduce the side effects of empagliflozin. Empagliflozin is an effective medication for treating diabetes, but it can cause some side effects. 1 It is important to understand the risks and benefits of empagliflozin before using it. 13 When using empagliflozin, you should see your doctor regularly and carefully monitor for any side effects.

Conclusion

Empagliflozin is an effective medication for treating type 2 diabetes, but it can cause some side effects. 1 It is important to understand the risks and benefits of empagliflozin before using it. 13 When using empagliflozin, you should see your doctor regularly and carefully monitor for any side effects.

Literature analysis of 20 papers
Positive Content
16
Neutral Content
1
Negative Content
3
Article Type
1
0
0
6
12
1.

Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report.

Author: ZeidanBassem S, BoaduCharles, HernandezAndrea, FrunziJohnathan, AdetulaItioye

Diabetes management
Acute pancreatitis

This case report highlights a rare case of acute pancreatitis in a 64-year-old female who recently initiated empagliflozin, an SGLT-2 inhibitor for type 2 diabetes. It emphasizes the potential for iatrogenic pancreatitis associated with empagliflozin and the importance of identifying medication-related causes.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

2.

Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats.

Author: KalantariElham, ZolbaninNaime Majidi, Ghasemnejad-BerenjiMorteza

Protects liver

Empagliflozin, an SGLT2 inhibitor, showed protective effects against methotrexate (MTX)-induced hepatotoxicity in rats by reducing oxidative stress. Higher doses of empagliflozin were more effective.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations.

Author: MaffeiPietro, BettiniSilvia, BusettoLuca, DassieFrancesca

Cardiovascular protection
Glycaemic control
Weight loss
DKA risk

This review examines the current evidence and recommendations for the use of SGLT2 inhibitors in the treatment of type 1 diabetes (T1D).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved study.

Author: ZannadFaiez, MacariSteven

Reduced heart failure symptoms
Reduced mortality risk

Empagliflozin is a new medication for the treatment of chronic heart failure. Empagliflozin was shown to reduce the risk of hospitalization for heart failure in a recent clinical trial.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial.

Author: PasquaMelissa-Rosina, OdabassianMadison, TsoukasMichael A, HaidarAhmad

Improved glycemic control

This study qualitatively and quantitatively assessed the thoughts and experiences of participants with type 1 diabetes who have used low doses of empagliflozin as an adjunct to hybrid closed-loop therapy.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

15.

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review.

Author: SupakulSopak, NishikawaYurika, TeramuraMasanori, TakaseTetsuro

Dehydration
Empagliflozin

This case study describes a patient with diabetes mellitus and heart failure who experienced severe dehydration and cardiac arrest after initiating empagliflozin treatment. The case highlights the importance of careful monitoring for dehydration, particularly in elderly patients and those with neurological deficits, especially when receiving empagliflozin.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.

Author: BoulangerCécile, StephenneXavier, DiederichJennifer, MounkoroPierre, ChevalierNathalie, FersterAlina, Van SchaftingenEmile, Veiga-da-CunhaMaria

Improve neutrophil function
Treat neutropenia

This study evaluated the efficacy of SGLT2 inhibitors in treating neutropenia associated with G6PC3 deficiency. Empagliflozin significantly decreased blood 1,5-AG and 1,5-AG6P in neutrophils, leading to improved or normalized neutrophil counts and allowing for discontinuation of GCSF. SGLT2 inhibitors may be a viable alternative for treating neutropenia in G6PC3 deficiency.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?

Author: KaczorMagdalena, GreczanMilena, KierusKarolina, Ehmke Vel Emczyńska-SeligaEwa, CiaraElżbieta, PiątosaBarbara, RokickiDariusz, KsiążykJanusz, Wesół-KucharskaDorota

Neutropenia treatment
G-CSF side effects

Glycogen storage disease type 1b (GSD1b) is a rare genetic disorder that can cause serious problems, including frequent infections and neutropenia. This study reports on the use of empagliflozin, a drug that lowers blood sugar, to treat neutropenia in patients with GSD1b. The results suggest that empagliflozin may be an effective and safe treatment option for neutropenia in GSD1b patients.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

18.

Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study.

Author: KakuKohei, YamamotoKazuhiro, FukushimaYumiko, MizunoSeiko, NittaDaisuke

Good effectiveness
Good tolerability

Empagliflozin was well tolerated and effective in Japanese patients with type 2 diabetes regardless of their body mass index.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.

Author: KakuKohei, YamamotoKazuhiro, FukushimaYumiko, LlievHristo, YasuiAtsutaka

Good tolerability
Improved blood pressure
Improved glycemic control
Reduced HbA1c
Reduced weight
Genitourinary infections
Hypoglycemia
Increased risk of fracture

This study found that empagliflozin was effective and generally well tolerated in Japanese patients with type 2 diabetes (T2D). Adverse drug reactions (ADRs) were consistent with its known safety profile.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.